Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 7/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | MGMT | P16455 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28863081 | 1.00 | CDK1 (0.48) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9393667 | 0.89 | PDPK1 (0.49) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL29424580 | 0.82 | XDH (0.44) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL5468651 | 0.80 | XDH (0.41) | XDHADORA2B | |
| SCHEMBL6899619 | 0.79 | POLA1 (0.53) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL29424586 | 0.77 | FAAH (0.43) | — | |
| SCHEMBL3630347 | 0.76 | GDA (0.56) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL10528232 | 0.74 | XDH (0.60) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL1684049 | 0.74 | GDA (0.58) | CDK2XDHPOLA1PDPK1GDA | |
| SCHEMBL29509029 | 0.74 | GDA (0.58) | CDK2XDHPOLA1PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017164615-A1 | METHOD FOR PREPARING 3'-AMINO-2',3'-DIDEOXYADENOSINE BY USING NUCLEOSIDE PHOSPHORYLASE DERIVED FROM BACILLUS | ST PHARM CO., LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| US-4145531-A | Process for producing 2'-substituted-D-ribofuranosyl purine compounds | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | CDK1 1757/4885CCNB1 2176/4885CCNA2 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.